Cefoxitin

Identification

Summary

Cefoxitin is a semi-synthetic, broad-spectrum antibiotic for parenteral administration used for the treatment of serious bacterial infections, such as urinary tract infection, blood infection, bone and joint infection, and lower respiratory tract infection.

Generic Name
Cefoxitin
DrugBank Accession Number
DB01331
Background

Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by Streptomyces lactamdurans.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 427.452
Monoisotopic: 427.050791293
Chemical Formula
C16H17N3O7S2
Synonyms
  • (6R,7S)-4-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[(thiophen-2-enyl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • Cefoxitin
  • Cefoxitina
  • Cefoxitine
  • Cefoxitinum
  • Ceftoxitin
  • Cephoxitin
  • CFX
  • Rephoxitin
External IDs
  • J01DC01

Pharmacology

Indication

For the treatment of serious infections caused by susceptible strains microorganisms.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAnimal bite••• •••••
Treatment ofBacterial infections••••••••••••
Treatment ofBacterial urinary tract infections••••••••••••
Treatment ofEndometritis••••••••••••
Treatment ofGynecological infection••••••••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria.

Mechanism of action

The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

TargetActionsOrganism
AD-alanyl-D-alanine carboxypeptidase DacC
inhibitor
Escherichia coli (strain K12)
AD-alanyl-D-alanine carboxypeptidase DacA
inhibitor
Escherichia coli (strain K12)
AD-alanyl-D-alanine endopeptidase
inhibitor
Escherichia coli (strain K12)
AD-alanyl-D-alanine carboxypeptidase DacB
inhibitor
Escherichia coli (strain K12)
APenicillin-binding protein 1A
inhibitor
Escherichia coli (strain K12)
APenicillin-binding protein 1B
inhibitor
Escherichia coli (strain K12)
APeptidoglycan synthase FtsI
inhibitor
Escherichia coli (strain K12)
APenicillin-binding protein 3
inhibitor
Streptococcus pneumoniae
APenicillin-binding protein 1b
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2a
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 1A
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
APenicillin-binding protein 2B
inhibitor
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Minimal (approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period).

Route of elimination

Approximately 85 percent of cefoxitin is excreted unchanged by the kidneys over a 6-hour period, resulting in high urinary concentrations. Cefoxitin passes into pleural and joint fluids and is detectable in antibacterial concentrations in bile.

Half-life

The half-life after an intravenous dose is 41 to 59 minutes.

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

The acute intravenous LD50 in the adult female mouse and rabbit was about 8.0 g/kg and greater than 1.0 g/kg, respectively. The acute intraperitoneal LD50 in the adult rat was greater than 10.0 g/kg.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirCefoxitin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Cefoxitin.
AceclofenacThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Aceclofenac.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Cefoxitin is combined with Acenocoumarol.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Cefoxitin sodiumQ68050H03T33564-30-6GNWUOVJNSFPWDD-XMZRARIVSA-M
International/Other Brands
Cefoctin (Teva) / Cenomicin (Daiichi-Seiyaku) / Mefoxitin (Merck)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Cefoxitin and DextroseInjection, solution2 g/50mLIntravenousB. Braun Medical Inc.2006-03-10Not applicableUS flag
Cefoxitin and DextroseInjection, solution1 g/50mLIntravenousB. Braun Medical Inc.2006-03-10Not applicableUS flag
Cefoxitin for InjectionPowder, for solution1 g / vialIntramuscular; IntravenousTEVA Canada Limited1995-12-31Not applicableCanada flag
Cefoxitin for InjectionPowder, for solution10 g / vialIntramuscular; IntravenousTEVA Canada Limited2000-01-01Not applicableCanada flag
Cefoxitin for InjectionPowder, for solution2 g / vialIntramuscular; IntravenousTEVA Canada Limited1995-12-31Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CefoxitinInjection, powder, for solution10 g/1IntravenousWG Critical Care, LLC2013-10-01Not applicableUS flag
CefoxitinInjection, powder, for solution1 g/1IntravenousHikma Farmaceutica2010-03-122010-03-12US flag
CefoxitinInjection, powder, for solution2 g/1IntravenousHikma Pharmaceuticals USA Inc.2010-03-12Not applicableUS flag
CefoxitinInjection, powder, for solution2 g/1IntravenousApotex Corporation2008-02-272018-10-31US flag
CefoxitinInjection, powder, for solution10 g/1IntravenousHikma Pharmaceuticals USA Inc.2010-02-26Not applicableUS flag

Categories

ATC Codes
J01DC01 — Cefoxitin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cephalosporin 3'-carbamates. These are cephalosporins that are substituted at the 3'-position by a carbamate group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephalosporin 3'-carbamates
Alternative Parents
Cephamycins / N-acyl-alpha amino acids and derivatives / 1,3-thiazines / Thiophenes / Tertiary carboxylic acid amides / Carbamate esters / Heteroaromatic compounds / Secondary carboxylic acid amides / Azetidines / Organic carbonic acids and derivatives
show 10 more
Substituents
Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Azetidine / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cephalosporin, semisynthetic derivative, cephamycin (CHEBI:209807)
Affected organisms
  • Enteric bacteria and other eubacteria

Chemical Identifiers

UNII
6OEV9DX57Y
CAS number
35607-66-0
InChI Key
WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
InChI
InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1
IUPAC Name
(6R,7S)-3-[(carbamoyloxy)methyl]-7-methoxy-8-oxo-7-[2-(thiophen-2-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@]2(NC(=O)CC1=CC=CS1)OC)C(O)=O

References

Synthesis Reference

Pandurang Deshpande, Bhausaheb Khadangale, "Process for the preparation of cefoxitin." U.S. Patent US20060252928, issued November 09, 2006.

US20060252928
General References
Not Available
Human Metabolome Database
HMDB0015426
KEGG Drug
D02345
KEGG Compound
C06887
PubChem Compound
441199
PubChem Substance
46505845
ChemSpider
389981
BindingDB
50335563
RxNav
2189
ChEBI
209807
ChEMBL
CHEMBL996
ZINC
ZINC000003830449
Therapeutic Targets Database
DAP000452
PharmGKB
PA448856
PDBe Ligand
CFX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefoxitin
PDB Entries
4kow
FDA label
Download (76.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedOtherAntibiotic pre-surgical prophylaxis1
4TerminatedTreatmentUrinary Tract Infection1
3Active Not RecruitingTreatmentPancreatic Cancer / Pancreatic Diseases1
3RecruitingPreventionAntibiotics Prophylaxis / Surgery, Colorectal1
2Unknown StatusPreventionEndometritis / Infection; Cesarean Section / Wound Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Apotex Inc.
  • APP Pharmaceuticals
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bioniche Pharma
  • GC Hanford Manufacturing Co.
  • GlaxoSmithKline Inc.
  • Hikma Pharmaceuticals
  • Merck & Co.
  • Orchid Healthcare
  • Sagent Pharmaceuticals
  • West-Ward Pharmaceuticals
Dosage Forms
FormRouteStrength
Injection, powder, for solution
Injection, powder, for solutionIntramuscular
Injection, powder, for solutionIntravenous1 g/10mL
Injection, powder, for solutionIntravenous10 g/100mL
Injection, powder, for solutionIntravenous100 g/1
Injection, powder, for solutionIntravenous2 g/10mL
Powder, for solutionIntravenous1 g/1
Powder, for solutionIntravenous2 g/1
Powder, for solutionIntramuscular; Intravenous1 g / vial
Powder, for solutionIntramuscular; Intravenous10 g / vial
Powder, for solutionIntramuscular; Intravenous2 g / vial
PowderIntravenous
InjectionIntramuscular500 MG
InjectionIntravenous500 MG
Injection, powder, for solutionIntramuscular; Parenteral1 G/2ML
Injection, powder, for solutionIntravenous1 g/1
Injection, powder, for solutionIntravenous10 g/1
Injection, powder, for solutionIntravenous2 g/1
Injection, powder, for solutionIntravenous; Parenteral1 G/10ML
Injection, powder, for solutionIntravenous; Parenteral2 G/20ML
Injection, solutionIntravenous1 g/50mL
Injection, solutionIntravenous2 g/50mL
Powder, for solutionIntravenous1 g / vial
Powder, for solutionIntravenous2 g / vial
Powder, for solutionIntravenous10 g / vial
PowderIntravenous500 mg/1vial
Prices
Unit descriptionCostUnit
Cefoxitin 10 gm vial112.25USD vial
Cefoxitin 2 gm vial26.28USD vial
Cefoxitin 2 gm piggyback bag22.56USD each
Cefoxitin 1 gm vial13.12USD vial
Cefoxitin 1 gm piggyback bag12.3USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)165-167Christiansen, B.G. and Firestone, R.A.; US. Patent 3,775,410; November 27, 1973; assigned Hazen, G.C.; U.S. Patent 3,780,033; December 18, 1973; assigned to Merck & Company, Inc.
logP-0.02SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.195 mg/mLALOGPS
logP0.22ALOGPS
logP0.29Chemaxon
logS-3.3ALOGPS
pKa (Strongest Acidic)3.39Chemaxon
pKa (Strongest Basic)-3.8Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area148.26 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity98.76 m3·mol-1Chemaxon
Polarizability39.47 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.7203
Blood Brain Barrier-0.9952
Caco-2 permeable-0.7898
P-glycoprotein substrateSubstrate0.8198
P-glycoprotein inhibitor INon-inhibitor0.8831
P-glycoprotein inhibitor IINon-inhibitor0.9715
Renal organic cation transporterNon-inhibitor0.9085
CYP450 2C9 substrateNon-substrate0.8655
CYP450 2D6 substrateNon-substrate0.8241
CYP450 3A4 substrateSubstrate0.5389
CYP450 1A2 substrateNon-inhibitor0.786
CYP450 2C9 inhibitorNon-inhibitor0.8214
CYP450 2D6 inhibitorNon-inhibitor0.8642
CYP450 2C19 inhibitorNon-inhibitor0.7954
CYP450 3A4 inhibitorNon-inhibitor0.9312
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8753
Ames testNon AMES toxic0.6912
CarcinogenicityNon-carcinogens0.9329
BiodegradationNot ready biodegradable0.979
Rat acute toxicity1.6623 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9951
hERG inhibition (predictor II)Non-inhibitor0.8518
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0005-9324000000-05cb1df27c44fb10d1f0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0009200000-6482009cde6e3d8e3ace
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-0159000000-0437b91cd9b6026a45c9
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-016s-2059400000-38b513f0d0afafd7ded4
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-05mx-5179000000-37b13176f20989d23e18
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-5779100000-fe98f705db46132fe035
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-002p-9861000000-a185b44d446d00848a56
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-206.7217374
predicted
DarkChem Lite v0.1.0
[M-H]-206.7761374
predicted
DarkChem Lite v0.1.0
[M-H]-188.00989
predicted
DeepCCS 1.0 (2019)
[M+H]+207.7868374
predicted
DarkChem Lite v0.1.0
[M+H]+206.8537374
predicted
DarkChem Lite v0.1.0
[M+H]+190.3679
predicted
DeepCCS 1.0 (2019)
[M+Na]+207.3497374
predicted
DarkChem Lite v0.1.0
[M+Na]+207.6639374
predicted
DarkChem Lite v0.1.0
[M+Na]+196.78415
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.
Gene Name
dacC
Uniprot ID
P08506
Uniprot Name
D-alanyl-D-alanine carboxypeptidase DacC
Molecular Weight
43608.595 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Removes C-terminal D-alanyl residues from sugar-peptide cell wall precursors.
Gene Name
dacA
Uniprot ID
P0AEB2
Uniprot Name
D-alanyl-D-alanine carboxypeptidase DacA
Molecular Weight
44443.62 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Cell wall formation. May play a specialized role in remodeling the cell wall. Specifically hydrolyzes the DD-diaminopimelate-alanine bonds in high-molecular-mass murein sacculi.
Gene Name
pbpG
Uniprot ID
P0AFI5
Uniprot Name
D-alanyl-D-alanine endopeptidase
Molecular Weight
33887.085 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Not involved in transpeptidation but exclusively catalyzes a DD-carboxypeptidase and DD-endopeptidase reaction.
Gene Name
dacB
Uniprot ID
P24228
Uniprot Name
D-alanyl-D-alanine carboxypeptidase DacB
Molecular Weight
51797.85 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
mrcA
Uniprot ID
P02918
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
93635.545 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Cell wall formation. Synthesis of cross-linked peptidoglycan from the lipid intermediates. The enzyme has a penicillin-insensitive transglycosylase N-terminal domain (formation of linear glycan str...
Gene Name
mrcB
Uniprot ID
P02919
Uniprot Name
Penicillin-binding protein 1B
Molecular Weight
94291.875 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Peptidoglycan glycosyltransferase activity
Specific Function
Essential cell division protein that is required for the synthesis of peptidoglycan at the division septum (PubMed:1103132, PubMed:9614966). Catalyzes the synthesis of cross-linked peptidoglycan fr...
Gene Name
ftsI
Uniprot ID
P0AD68
Uniprot Name
Peptidoglycan synthase FtsI
Molecular Weight
63876.925 Da
References
  1. Matsuhashi M, Tamaki S: Enzymatic studies on the mechanism of action of cefoxitin. Correlation between the affinities of cefoxitin to penicillin-binding proteins and its rates of inhibition of the respective penicillin-sensitive reactions in E. coli. J Antibiot (Tokyo). 1978 Dec;31(12):1292-5. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function
Not Available
Gene Name
pbp3
Uniprot ID
Q75Y35
Uniprot Name
Penicillin-binding protein 3
Molecular Weight
45209.84 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp1b
Uniprot ID
Q7CRA4
Uniprot Name
Penicillin-binding protein 1b
Molecular Weight
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Transferase activity, transferring acyl groups
Specific Function
Not Available
Gene Name
pbp2a
Uniprot ID
Q8DNB6
Uniprot Name
Penicillin-binding protein 2a
Molecular Weight
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Penicillin binding
Specific Function
Cell wall formation.
Gene Name
pbpA
Uniprot ID
Q8DR59
Uniprot Name
Penicillin-binding protein 1A
Molecular Weight
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Not Available
Specific Function
Penicillin binding
Gene Name
penA
Uniprot ID
P0A3M6
Uniprot Name
Penicillin-binding protein 2B
Molecular Weight
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [Article]

Enzymes

Kind
Protein
Organism
Bacillus licheniformis
Pharmacological action
Unknown
Actions
Substrate
General Function
Beta-lactamase activity
Specific Function
Not Available
Gene Name
penP
Uniprot ID
P00808
Uniprot Name
Beta-lactamase
Molecular Weight
33995.36 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Song W, Lee KM, Kim HS, Kim JS, Kim J, Jeong SH, Roh KH: Clonal spread of both oxyimino-cephalosporin- and cefoxitin-resistant Klebsiella pneumoniae isolates co-producing SHV-2a and DHA-1 beta-lactamase at a burns intensive care unit. Int J Antimicrob Agents. 2006 Dec;28(6):520-4. Epub 2006 Nov 13. [Article]
  4. d'Azevedo PA, Goncalves AL, Musskopf MI, Ramos CG, Dias CA: Laboratory tests in the detection of extended spectrum beta-lactamase production: National Committee for Clinical Laboratory Standards (NCCLS) screening test, the E-test, the double disk confirmatory test, and cefoxitin susceptibility testing. Braz J Infect Dis. 2004 Oct;8(5):372-7. Epub 2005 Mar 17. [Article]
  5. Ke YY, Lin TH: A theoretical study on the activation of Ser70 in the acylation mechanism of cephalosporin antibiotics. Biophys Chem. 2005 Apr 22;114(2-3):103-13. Epub 2004 Nov 30. [Article]

Drug created at June 13, 2005 13:24 / Updated at March 18, 2024 16:48